2019
DOI: 10.1007/s12975-019-00707-w
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Role of a Cysteine Precursor, OTC, in Ischemic Stroke Is Mediated by Improved Proteostasis in Mice

Abstract: Oxidative stress aggravates brain injury following ischemia/reperfusion (I/R). We previously showed that ubiquilin-1 (Ubqln1), a ubiquitin-like protein, improves proteostasis and protects brains against oxidative stress and I/R induced brain injury. Here, we demonstrate that a small molecule compound, L-2-oxothiazolidine-4-carboxylic acid (OTC) that functions as a precursor of cysteine, upregulated Ubqln1 and protected cells against oxygen glucose deprivation-induced cell death in neuronal cultures. Further, t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
30
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 35 publications
(30 citation statements)
references
References 46 publications
0
30
0
Order By: Relevance
“…Electrophoresis, transfer, and Western blot analysis of proteins were performed according to previously described methods [ 28 ]. The primary antibodies used were anti-CryAB (1:1000, Abcam; #ab13496), anti-Argonaute 1 (Argo1) (1:1000, Cell Signaling Technology, #5053, Lot 1), anti-Tsg101 (1:1000, Santa Cruz Biotechnology, #sc7964, Lot F0217), anti-ubiquitin (Ub) (1:1000, Cell Signaling Technology, #3936, Lot 14), anti-IL-1β (1:1000, Cell Signaling Technology, #63124), anti-IL-6 (1:1000, Cell Signaling Technology, #12912), anti-TNFα (1:1000, Cell Signaling Technology, #11948), and anti-β-actin (1:1000, Santa Cruz Biotechnology, #sc-1616, Lot G1615).…”
Section: Methodsmentioning
confidence: 99%
“…Electrophoresis, transfer, and Western blot analysis of proteins were performed according to previously described methods [ 28 ]. The primary antibodies used were anti-CryAB (1:1000, Abcam; #ab13496), anti-Argonaute 1 (Argo1) (1:1000, Cell Signaling Technology, #5053, Lot 1), anti-Tsg101 (1:1000, Santa Cruz Biotechnology, #sc7964, Lot F0217), anti-ubiquitin (Ub) (1:1000, Cell Signaling Technology, #3936, Lot 14), anti-IL-1β (1:1000, Cell Signaling Technology, #63124), anti-IL-6 (1:1000, Cell Signaling Technology, #12912), anti-TNFα (1:1000, Cell Signaling Technology, #11948), and anti-β-actin (1:1000, Santa Cruz Biotechnology, #sc-1616, Lot G1615).…”
Section: Methodsmentioning
confidence: 99%
“…Electrophoresis, transfer and western blot analysis of proteins were according to previously described methods 43 . The primary antibodies used were anti-CryAB (1:1000, Abcam; #ab13496), anti-proteasome 20S beta 1i subunit (1:1000, Enzo life sciences, #BML-PW8205; Lot 10071464), anti-proteasome 20S beta 2i subunit (1:1000, Enzo life sciences, #BML-PW8350; Lot 11281405), anti-proteasome 20S beta 5i subunit (1:1000, Cell Signaling Technology, #13726; Lot 1), anti-Argonaute 1 (Argo1) (1:1000, Cell Signaling Technology, #5053, Lot 1), anti-Tsg101 (1:1000, Santa Cruz Biotechnology, #sc7964, Lot F0217), anti-ubiquitin (Ub) (1:1000, Cell Signaling Technology, #3936, Lot 14), anti-K48-linkage specific polyubiquitin (1:1000, Cell Signaling Technology, #8081; Lot 2), and anti-actin (1:1000, Santa Cruz Biotechnology, #sc-1616, Lot G1615).…”
Section: Methodsmentioning
confidence: 99%
“…Primary mouse cortical neurons were prepared from wild-type C57BL/6J mice as previously described 43 . The cells were cultured in poly-ornithine-coated 12-well plates for 7 days and then treated with exosomes (10 µg/ml) isolated either from the Ntg or CryAB R120G mouse blood and after 24 hours, the exosome-treated neuronal cultures were stained for protein aggregates using a Proteostat Aggresome Detection Kit (Enzo Life Sciences, #ENZ-51035) by following the manufacturer provided protocol.…”
Section: Methodsmentioning
confidence: 99%
“…GSH is an important antioxidant synthesized in cells, which detoxifies ROS. However, the therapeutic effect of OTC diminishes in Ubqln1 knockout mice after cerebral stroke, suggesting that the therapeutic potential of OTC involves both antioxidative property and proteostasis enhancement [113]. Another study from the same group also demonstrated that the administration of nialamide (a non-selective monoamine oxidase inhibitor) in the ischemic stroke mouse model can also upregulate Ubqln1, and in turn reduces oxidative stress as well as neuroinflammation ( Figure 6) [114].…”
Section: Er Stress Components and Ich Therapeutic Strategiesmentioning
confidence: 98%